Keyi Zhu, Ph.D.
Affiliations: | 2007 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Molecular BiologyGoogle:
"Keyi Zhu"Parents
Sign in to add mentor| David J. McConkey | grad student | 2007 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (The effects of proteasome inhibition on angiogenesis and autophagy in human prostate cancer cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| White MC, Schroeder RD, Zhu K, et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene |
| Jia H, Song L, Cong Q, et al. (2016) The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network. Oncogene |
| Jinesh GG, Mokkapati S, Zhu K, et al. (2016) Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks. Apoptosis : An International Journal On Programmed Cell Death |
| Zhu K, Dunner K, McConkey DJ. (2010) Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene. 29: 451-62 |
| Zhu K, Chan W, Heymach J, et al. (2009) Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Research. 69: 1836-43 |
| McConkey DJ, Zhu K. (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 11: 164-79 |
| Canfield SE, Zhu K, Williams SA, et al. (2006) Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Molecular Cancer Therapeutics. 5: 2043-50 |
| Zhu K, Pino M, Siefker-Radtke AO, et al. (2006) AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo. Journal of Clinical Oncology. 24: 13109-13109 |
| Lashinger LM, Zhu K, Williams SA, et al. (2005) Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Research. 65: 4902-8 |